SCHEMBL5154986

SCHEMBL5154986

O=C1CSC(c2ccc3c(c2)CCO3)N1CCOc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
TDP1 Q9NUW8 3/20 0.42
PDE5A O76074 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
GRM5 P41594 1/20 0.40
KCNA5 P22460 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CACNA1B Q00975 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5153316 0.90 PTGS1 (0.57) ALDH1A1HTTNPSR1PTGS1PTGS2
SCHEMBL5156944 0.77 PTGS1 (0.54) PTGS1PTGS2TDP1MEN1KMT2A
SCHEMBL5151382 0.77 ALDH1A1 (0.54) ALDH1A1HTTNPSR1SMN1; SMN2TDP1
SCHEMBL5151547 0.74 CACNA1B (0.51) PTGS1PTGS2TDP1KMT2ACACNA1B
SCHEMBL5156411 0.73 KMT2A (0.47) ALDH1A1SMN1; SMN2TDP1MEN1KMT2A
SCHEMBL5151385 0.72 KMT2A (0.38) ALDH1A1HTTNPSR1SMN1; SMN2MEN1
SCHEMBL5155040 0.69 PTGS1 (0.59) ALDH1A1HTTNPSR1PTGS1PTGS2
SCHEMBL5156790 0.68 PTGS1 (0.60) ALDH1A1HTTNPSR1PTGS1PTGS2
SCHEMBL747785 0.68 HCRTR2 (0.46) ALDH1A1HTTNPSR1SMN1; SMN2TDP1
SCHEMBL5149765 0.67 PTGS1 (0.56) ALDH1A1HTTNPSR1PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223754-B2 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-03-22 US disclosed
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-07-07 US disclosed
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders TRPV2, RYR2, VDAC2 ALDH1A1 3381/4885HTT 2923/4885NPSR1 2921/4885
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I ALDH1A1 1370/4885HTT 2177/4885NPSR1 3392/4885
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I ALDH1A1 1370/4885HTT 2177/4885NPSR1 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.